Updates are available Correction dated 2023-08-11
Click to view Correction: https://doi.org/10.1038/s41541-023-00723-w
-
Authors
Hayashi, Clifford T. H.
Cao, Yi
Clark, Leor C. https://orcid.org/0000-0003-4530-5855
Tripathi, Abhai K. https://orcid.org/0000-0001-9848-0142
Zavala, Fidel https://orcid.org/0000-0002-1414-6196
Dwivedi, Garima
Knox, James
Alameh, Mohamad-Gabriel
Lin, Paulo J. C.
Tam, Ying K.
Weissman, Drew
Kumar, Nirbhay https://orcid.org/0000-0002-0358-4924
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (AI47089)
George Washington University
- License Information
-
More Information
Article History
Received: 25 July 2022
Accepted: 3 November 2022
First Online: 1 December 2022
Change Date: 11 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41541-023-00723-w
Competing interests
: In accordance with the George Washington University and University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that D.W. is named on a patent describing the use of nucleoside-modified mRNA in lipid nanoparticles as a vaccine platform. N.K. and D.W. are named as inventors on a provisional patent application filed by the George Washington University. P.L. and Y.T. are employees of Acuitas Therapeutics, a company involved in the development of mRNA-LNP therapeutics. D.W., and M.-G.A. are named on patents that describe lipid nanoparticles for delivery of nucleic acid therapeutics, including mRNA and the use of modified mRNA in lipid nanoparticles as a vaccine platform.
